Rheumatoid Arthritis: The 45+ Market in the United States for Drugs and Biologics

Table of Contents

Chapter One: Executive Summary

• Background
• Scope and Methodology
• Size and Growth of Market
• Market Trends and Factors

Chapter Two: Introduction

• Background
• Population Demographics
• Epidemiology and Pathology of Rheumatoid Arthritis

Chapter Three: Rheumatoid Arthritis Therapeutics

• Current Approaches
• Approaches to Rheumatoid Arthritis Therapy
  • Patient Education
  • Rest and Exercise
  • Diet
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
  • Steroids (Corticosteroids, Glucocorticoids)
  • Cytokine Targeted Therapy
  • Other Approaches
• Emerging Therapeutic Approaches
  • Tumor Necrosis Factor-a (TNF-a) Inhibitors
  • Interleukin-1 (IL-1)Inhibitors
  • p38 MAP Kinase Inhibitors
  • Interleukin-6 (IL-6) Inhibitors
  • Interleukin-15 (IL-15) Inhibitors
  • HC-gp-39 (Human Cartilage-glycoprotein-39) Desensitizers
  • C5 (Complement) Inhibitors
  • Vaccines
  • Other Approaches

Chapter Four: Market Analysis

• Market Size and Growth
• Competitive Outlook
• Market Trends

Chapter Five: Company Profiles

• Overview
• Abbott Laboratories
• AstraZeneca
• Biogen, Inc.
• Chugai Pharmaceuticals USA, LLC
• Corixa Corporation
• Fujisawa Pharmaceutical Co., Ltd.
• Lifestyle Therapeutics - Camrose, Inc.
• Medarex, Inc.
• Pfizer
• Schering-Plough
• Vertex Pharmaceuticals, Inc.
• Viron Therapeutics, Inc.
• Wyeth

Chapter Six: Conclusions and Strategic Implications

• First Conclusion
• Second Conclusion
• Third Conclusion
• Fourth Conclusion
• Fifth Conclusion
• Sixth Conclusion
• Seventh Conclusion
• Eighth Conclusion
• Ninth Conclusion
• Tenth Conclusion

APPENDIX A: Company Directory

List of Exhibits

Chapter One: Executive Summary

• Table 1-1: Estimated TAM Potential for the Age-Related Segments for Rheumatoid Arthritis Therapeutics in the United States Markets, 2003-2013
• Table 1-2: Estimated SAM Potential for the Age-Related Segments for Rheumatoid Arthritis Therapeutics in the United States Markets 2003-2013
• Figure 1-1: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the Middle-Aged and Elderly Market Segments 2003-2013
• Figure 1-2: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the 45- to 54-Year-Old Market Segment 2003-2013
• Figure 1-3: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the 55- to 64-Year-Old Market Segment 2003-2013
• Figure 1-4: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the 65- to 74-Year-Old Market Segment 2003-2013
• Figure 1-5: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the 75+ Year-Old Market Segment 2003-2013

Chapter Two: Introduction

• Figure 2-1: Growth of the World�fs Elderly (60+ Years) Population 2001-2025
• Figure 2-2: Population Distribution of the United States by Age and Sex 1999 and 2025
• Figure 2-3: The Growing United States Population 2003-2013
• Figure 2-4: Increasing Median Age of the United States Population
• Figure 2-5: Increasing Mean Age of the United States Population
• Table 2-1: Aging of the United States Population in the Age Groups 45 Years and Older 2003-2013
• Figure 2-6: Aging Trends in the United States Population for the Age
• Groups 45 Years and Older 2003-2013
• Figure 2-7: Changes in the Composition of the 45+Year-Old and Older Age Segment in the United States 2003 and 2013
• Table 2-2: Older Population Groups as Percentages of the Total United States Population by Age Group 2003-2013
• Figure 2-8: Aging Trends by Percentage of the United States Population for the Age Groups 45 Years and Older 2003-2013
• Table 2-3: Prevalence of Rheumatoid Arthritis Cases in the United States
• for the Total Population and Those 45 Years of Age and Older 2003-2013 Figure 2-9: Trending in United States Rheumatoid Arthritis Cases in the 45+ Year Old Age Group 2003-2013

Chapter Three: Rheumatoid Arthritis Therapeutics

• Table 3-1: Currently Marketed Products for the Treatment of Rheumatoid Arthritis
• Table 3-2: Recommended Patient Monitoring for the Administration of DMARDS in the Treatment of Rheumatoid Arthritis Table 3-3: Rheumatoid Arthritis Therapeutics in Development

Chapter Four: Market Analysis

• Table 4-1: United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics 2003-2013
• Figure 4-1: Trending in the United States Total and Serviceable
• Available Market Potential for Rheumatoid Arthritis Therapeutics 2003-2013
• Table 4-2: United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics in the 45+ Age Population 2003-2013
• Figure 4-2: Trending in the United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics for the 45- to 54-Year-Old Age Group 2003-2013
• Figure 4-3: Trending in the United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics for the 55- to 64-Year-Old Age Group 2003-2013
• Figure 4-4: Trending in the United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics for the 65- to 74-Year-Old Age Group 2003-2013
• Figure 4-5: Trending in the United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics for the 65- to 74-Year-Old Age Group 2003-2013
• Table 4-6: Currently Marketed and Potential Competitive Products for the Treatment of Rheumatoid Arthritis